Recurrent Nasopharynx Carcinoma Clinical Trial
Official title:
Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
PRIMARY OBJECTIVES:
I. Objective tumor response to nivolumab in patients with previously treated recurrent and/or
metastatic nasopharyngeal carcinoma (NPC) based on Response Evaluation Criteria in Solid
Tumors (RECIST) criteria version 1.1.
SECONDARY OBJECTIVES:
I. Tumor response to nivolumab based on immune-related response criteria (IRC). II. Duration
of response. III. Progression-free survival and overall survival. IV. Safety and
tolerability.
TERTIARY OBJECTIVES:
I. To investigate the effect of nivolumab on tumor burden by analyzing the clearance of
plasma Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) during the first 4-6 weeks of
treatment.
II. To investigate the association between treatment outcome and immunological markers: a)
Intratumoral expression of programmed cell death 1 (PD-1) and programmed cell death-ligand
(PD-L1) in archived NPC tissues (mandatory); b) Serum absolute lymphocyte count at baseline
and post-treatment (mandatory); and c) Plasma cytokine levels at baseline and serially during
the first 8 weeks of treatment; d) Expression of PD-1 in cluster of differentiation (CD)8+ T
cells in tumor infiltrating lymphocytes (TIL) at baseline (optional).
III. To investigate functional magnetic resonance imaging (MRI) sequences as an early
predictor of response to nivolumab (optional only at Chinese University of Hong Kong [CUHK]).
OUTLINE:
Patients receive nivolumab intravenously (IV) over approximately 60 minutes on days 1 and 15.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 3 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02538510 -
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
| Terminated |
NCT02137096 -
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
|
Phase 3 | |
| Terminated |
NCT02706691 -
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
|
Phase 2 |